CVD biomarkers and kidney function

## Cardiovascular disease protein biomarkers are associated with kidney function: the

#### **Framingham Heart Study**

Amena Keshawarz, PhD, MPH; <sup>a,b</sup> Shih-Jen Hwang, PhD; <sup>a,b</sup> Gha Young Lee, BS; <sup>a,b</sup> Zhi Yu, MB,

PhD;<sup>c,d,e</sup> Chen Yao, PhD;<sup>a,b</sup> Anna Köttgen, MD, MPH<sup>f,g</sup>; Daniel Levy, MD<sup>a,b</sup>

Affiliations:

<sup>a</sup> Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood

Institute, National Institutes of Health, Bethesda, MD, USA

<sup>b</sup> Framingham Heart Study, Framingham, MA, USA

<sup>c</sup> Broad Institute of Harvard and MIT, Cambridge, Massachusetts

<sup>d</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,

Maryland

<sup>e</sup> Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University,

Baltimore, Maryland

<sup>f</sup> Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center - University of

Freiburg, Freiburg, Germany

<sup>g</sup> Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,

MD

Short title: CVD biomarkers and kidney function

Corresponding author:

Daniel Levy, MD, Framingham Heart Study

73 Mt. Wayte Avenue

Framingham, MA 01702

CVD biomarkers and kidney function

Phone: (508) 872-6556

levyd@nih.gov

Number of tables: 3

Number of figures: 1

Abstract word count: 297

Body text word count: 3,890

**Keywords:** chronic kidney disease, cardiovascular disease, proteomics, Mendelian randomization

CVD biomarkers and kidney function

1	Background. Biomarkers common to chronic kidney disease (CKD) and cardiovascular
2	disease (CVD) may reflect early impairments underlying both diseases.
3	Methods. We evaluated associations of 71 CVD-related plasma proteins measured in
4	2,873 Framingham Heart Study (FHS) Offspring cohort participants with cross-sectional
5	continuous eGFR and with longitudinal change in eGFR from baseline to follow-up ( $\Delta$ eGFR).
6	We also evaluated the associations of the 71 CVD proteins with the following dichotomous
7	secondary outcomes: prevalent CKD stage $\geq$ 3 (cross-sectional), new-onset CKD stage $\geq$ 3
8	(longitudinal), and rapid decline in eGFR (longitudinal). Proteins significantly associated with
9	eGFR and $\Delta$ eGFR were subsequently validated in 3,951 FHS Third Generation cohort
10	participants and were tested using Mendelian randomization (MR) analysis to infer putatively
11	causal relations between plasma protein biomarkers and kidney function.
12	Results. In cross-sectional analysis, 37 protein biomarkers were significantly associated
13	with eGFR at FDR<0.05 in the FHS Offspring cohort and 20 of these validated in the FHS Third
14	Generation cohort at p<0.05/37. In longitudinal analysis, 27 protein biomarkers were
15	significantly associated with $\Delta eGFR$ at FDR<0.05 and 12 of these were validated in the FHS
16	Third Generation cohort at p<0.05/27. Additionally, 35 protein biomarkers were significantly
17	associated with prevalent CKD, five were significantly associated with new-onset CKD, and 17
18	were significantly associated with rapid decline in eGFR. MR suggested putatively causal
19	relations of melanoma cell adhesion molecule (MCAM; -0.011±0.003 mL/min/1.73m <sup>2</sup> , p=5.11E-
20	5) and epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1; -
21	$0.006\pm0.002$ mL/min/1.73m <sup>2</sup> , p=0.0001) concentration with eGFR.
22	Discussion/Conclusions: Eight protein biomarkers were consistently associated with

23 eGFR in cross-sectional and longitudinal analysis in both cohorts and may capture early kidney

CVD biomarkers and kidney function

- 24 impairment; others were implicated in association and causal inference analyses. A subset of
- 25 CVD protein biomarkers may contribute causally to the pathogenesis of kidney impairment and
- 26 should be studied as targets for CKD treatment and early prevention.

CVD biomarkers and kidney function

## 28 Introduction

29 Chronic kidney disease (CKD) affects approximately 15% of the United States population, including more than 30% of adults over the age of 65 years.<sup>1,2</sup> Additionally, CKD is 30 among the leading global causes of mortality.<sup>3</sup> CKD is characterized by kidney damage and 31 impairment of filtration, which can culminate in kidney failure and death.<sup>4</sup> Kidney function is 32 33 frequently assessed clinically using estimated glomerular filtration rate (eGFR) based on serum creatinine concentration.<sup>5</sup> Early stages of CKD are often asymptomatic, and as such, CKD may 34 35 not be diagnosed until the development of substantial and often irreversible kidney dysfunction. 36 Thus, the identification of biomarkers of subclinical CKD that detect early kidney impairment 37 when treatment is more likely to be beneficial could prove to be important for disease prevention 38 and treatment.

39 CKD and cardiovascular disease (CVD) share common risk factors including diabetes mellitus (DM) and hypertension,<sup>6</sup> which are highly prevalent in adults with CKD and are 40 associated with subclinical and clinical CVD risk.<sup>7,8</sup> More than 50% of CKD cases in the United 41 States are attributable to DM,<sup>9</sup> and estimates of hypertension prevalence in patients with CKD 42 range between 40% and 60%.<sup>10-12</sup> Other shared mechanisms contributing to CKD and CVD 43 include inflammation,<sup>13</sup> activation of the renin-angiotensin-aldosterone system,<sup>13</sup> oxidative 44 stress,<sup>14,15</sup> and endothelial dysfunction.<sup>14</sup> Identifying biomarkers of kidney function may provide 45 46 insights into shared mechanisms of CKD and CVD.

Given the complex relationship between CKD and CVD, we aimed to identify protein
biomarkers of kidney dysfunction and CKD. To this end, we evaluated the associations of 71
CVD-related plasma proteins with CKD traits. These proteins were measured in 7,184
Framingham Heart Study (FHS) participants as a part of the Systems Approach to Biomarker

CVD biomarkers and kidney function

Research in Cardiovascular Disease (SABRe CVD) Initiative.<sup>16</sup> We tested the cross-sectional 51 52 and longitudinal associations of the 71 CVD proteins with kidney function traits. We also 53 conducted causal inference analyses using genetic variants associated with these proteins in 54 conjunction with genetic variants from a recently published large GWAS meta-analysis of kidney function traits.<sup>17</sup> 55 56 **Materials and Methods** 57 **Discovery** sample The discovery sample for this investigation included participants in the FHS Offspring<sup>18</sup> 58 59 cohort who attended the seventh examination cycle (1998-2001; baseline visit). At this visit, 60 serum and plasma samples were collected for measurement of serum creatinine and the 71 CVDrelated plasma proteins as part of the SABRe CVD Initiative.<sup>16</sup> Participants with a baseline 61  $eGFR \ge 60 \text{ mL/min}/1.73 \text{ m}^2$  who attended the FHS Offspring eighth examination cycle (2005-62 63 2008; follow-up visit) where a second serum creatinine measurement was obtained were 64 included in the longitudinal analysis of kidney function. 65 Participants with a medical record-confirmed diagnosis of heart failure or myocardial infarction at the baseline visit were excluded due to the effect of these diagnoses on biomarker 66 67 concentrations, yielding a final sample of 2,873 participants for cross-sectional analysis. There 68 were 2,393 participants who attended the follow-up examination and were eligible for inclusion 69 in the longitudinal analyses. All study protocols were approved by the Boston University 70 Medical Center institutional review board, and all study participants provided their 71 informed consent to participate in FHS research investigations. An overview of the study design 72 is presented in Figure 1. 73 Clinical examination and definitions

# CVD biomarkers and kidney function

74	Medical history and fasting blood samples were collected from all study participants at an
75	in-person research center examination. <sup>19</sup> Body mass index (BMI) was calculated as the ratio of
76	the participant's weight in kilograms to the square of height in meters. DM status was defined by
77	fasting blood glucose concentration $\geq$ 126 mg/dL or use of hypoglycemic medication. <sup>20</sup>
78	Hypertension was defined by systolic blood pressure $\geq 140$ mmHg, diastolic blood pressure $\geq 90$
79	mmHg, or use of antihypertensive medication. <sup>21</sup> Participants were defined as current smokers if
80	they reported smoking at least one cigarette per day on average during the previous year.
81	Prevalent CVD at the baseline study visit was defined as angina pectoris, coronary insufficiency,
82	cerebrovascular accident, atherothrombotic infarction of brain, transient ischemic attack, cerebral
83	embolism, intracerebral hemorrhage, subarachnoid hemorrhage, or intermittent claudication.
84	SABRe CVD biomarkers
85	Details of measurement of the 71 CVD-related proteins evaluated in this study have been
86	described previously. <sup>16</sup> Briefly, plasma samples were obtained from all participants at their
87	baseline clinical examinations and stored at -80°C. Samples were assayed and concentrations of
88	85 biomarkers were quantified using a modified ELISA sandwich approach on a Luminex xMAP
89	platform (Sigma-Aldrich, St. Louis, MO); 71 of these had detectable levels in at least 95% of
90	participant samples and were used in the present analyses. The 71 protein biomarkers used in this
91	study and their molecular weights are presented in Supplemental Table 1. Due to the
92	distribution of protein concentration values, inverse-rank normalized protein concentration
93	values were used in all statistical analyses.
94	Kidney function traits
95	Serum creatinine was measured using the modified Jaffe method (Roche Diagnostics,
96	Indianapolis, IN) and calibrated to National Health and Nutrition Examination Survey

97	(NHANES) III creatinine values. <sup>6</sup> eGFR, an estimate of kidney function, was calculated using
98	the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation. <sup>5</sup> The annual change in
99	eGFR ( $\Delta$ eGFR) was calculated for each participant as the follow-up minus baseline eGFR value
100	divided by the number of years between the two visits.
101	This study primarily focused on the continuous eGFR and $\Delta$ eGFR measures of kidney
102	function, with a secondary emphasis on dichotomous traits of CKD and rapid decline in eGFR.
103	Participants were categorized as having CKD stage $\geq$ 3 at the baseline visit if they had eGFR
104	values $<60 \text{ mL/min}/1.73 \text{ m}^2$ . New-onset CKD stage $\ge 3$ was defined as a follow-up eGFR $<60$
105	mL/min/1.73m <sup>2</sup> in participants who had eGFR values $\geq 60$ mL/min/1.73m <sup>2</sup> at baseline and a
106	concomitant $\geq$ 30% reduction in eGFR between baseline and follow-up. <sup>22</sup> Rapid decline in eGFR
107	was defined as a decline in eGFR of at least 3 mL/min/1.73m <sup>2</sup> per year between baseline and
108	follow-up.
109	Meta-analyzed GWAS of kidney function traits
110	Publicly available kidney trait GWAS summary statistics were obtained from the
111	CKDGen Consortium website (https://ckdgen.imbi.uni-freiburg.de/) as reported in a 2019 meta-
112	analysis that identified genetic variants associated with eGFR and CKD (eGFR $< 60$
113	mL/min/1.73m <sup>2</sup> ) in trans-ethnic and European Ancestry populations. <sup>17</sup>
114	Association of protein biomarkers with kidney traits
115	The primary kidney function outcomes were cross-sectional eGFR at the baseline visit,
116	and longitudinal $\Delta$ eGFR (i.e., eGFR at follow-up minus eGFR at baseline). The statistical
117	associations of each protein biomarker with these traits were evaluated using linear mixed
118	models.

119	The secondary kidney function outcomes evaluated were cross-sectional CKD at the
120	baseline visit, new-onset CKD at follow-up, and longitudinal rapid decline in eGFR. The
121	statistical associations between variation in the protein distribution and these dichotomous
122	kidney function traits were evaluated using logistic regression models.
123	All multivariable models were adjusted for the following kidney dysfunction risk factors
124	at baseline: age, sex, BMI, systolic blood pressure, total and HDL cholesterol, blood pressure
125	and/or lipid medication use, prevalent CVD, DM, and cigarette smoking status (current smokers
126	vs. non-smokers). Longitudinal analyses (i.e., models evaluating $\Delta eGFR$ , new-onset CKD, and
127	rapid decline in eGFR) were additionally adjusted for baseline eGFR, and only those participants
128	with available longitudinal data and who had a baseline $eGFR \ge 60 \text{ mL/min/}1.73\text{m}^2$ were
129	included in the model assessing new-onset CKD (n=2,257). We defined a "clinical model"
130	including all covariates except the protein biomarker of interest (i.e., reduced model), and a "full
131	model" including all covariates in the clinical model and the protein biomarker of interest.
132	For each protein biomarker, we evaluated the quantitative contribution of the protein
133	biomarker to variation in continuous kidney trait outcomes by comparing the goodness-of-fit $R^2$
134	value of the main and full models. The change in $R^2$ ( $\Delta R^2$ ) illustrates the incremental impact of
135	the addition of the protein biomarker over and above the clinical model. For the dichotomous
136	kidney function traits, we compared receiver operating characteristic (ROC) curves between the
137	clinical and full models using a contrast matrix to quantify the difference in the area under the
138	empirical ROC curve (i.e., the c-statistic). Results of the ROC curve comparison fit a chi-square
139	distribution, which was used to evaluate statistical significance. We calculated the false
140	discovery rate (FDR) for all associations, and FDR values <0.05 were interpreted as statistically

#### CVD biomarkers and kidney function

141 significant. Discovery protein-trait statistical analyses were performed in SAS version 9.4 (SAS

- 142 Institute, Cary, NC).
- 143 Validation of continuous kidney function outcomes

144 We conducted internal validation of the protein biomarkers significantly associated with 145 eGFR in cross-sectional discovery analysis and with  $\Delta$ eGFR in longitudinal discovery analyses. 146 Protein biomarkers that were significantly associated with eGFR in the FHS Offspring cohort were subsequently validated in 3,951 participants in the FHS Third Generation cohort<sup>23</sup> using 147 148 data from the first (2002-2005) and second (2009-2011) exams of this cohort. Third Generation 149 cohort participants were included in the internal validation sample if they had serum creatinine 150 and the SABRe plasma protein measurements and did not have a medical record-confirmed 151 diagnosis of heart failure or myocardial infarction. Statistical significance of the internal 152 validation analyses was defined as a Bonferroni-corrected p-value of 0.05/total number of 153 proteins included in the validation analysis. Validation analyses were performed in SAS version

154 9.4 (SAS Institute, Cary, NC).

### 155 <u>Two-sample Mendelian randomization (MR)</u>

We used a two-sample MR approach $^{24}$  to test the hypothesis that protein concentrations 156 157 associated with eGFR in the discovery and validation protein-trait analyses are causally related to continuous eGFR using data from published kidney trait GWAS.<sup>17</sup> Prior genome-wide 158 159 association studies (GWAS) of SABRe proteins in FHS participants identified protein quantitative trait loci (pQTL) variants for 57 of the 71 protein biomarkers.<sup>25</sup> Of these previously 160 161 identified variants, we considered only *cis*-pQTL variants for protein biomarkers that were 162 significantly associated with cross-sectional eGFR or longitudinal  $\triangle$ eGFR in the validation 163 analysis in the Third Generation cohort. *cis*-pQTL variants were defined as those single

CVD biomarkers and kidney function

164	nucleotide polymorphisms (SNPs) that were located 1 megabase upstream or downstream of the
165	protein-coding gene's transcription start site. Furthermore, cis-pQTL variants were pruned at
166	linkage disequilibrium $r^2 < 0.01$ , and only those that overlapped with SNPs from the kidney
167	function GWAS were used as instrumental variables for the protein biomarkers.
168	For protein biomarkers with only one pQTL variant as an instrumental variant in MR
169	analysis after pruning, the causal effect was calculated using the Wald test. For protein
170	biomarkers with more than one pQTL variant after pruning, the causal effect was calculated
171	using inverse-variance weighted meta-analyzed estimates. MR results were interpreted as
172	statistically significant after applying a Bonferroni correction for the total number of unique
173	protein biomarkers tested across all outcomes (i.e., p<0.05/n, where n is the number of protein-
174	trait associations tested).
175	In the case of multiple cis-pQTL variants contributing to a significant weighted causal
176	estimate, we conducted sensitivity analyses for heterogeneity. When more than two pQTL
177	variants or SNPs contributed to a significant weighted causal estimate, we additionally tested for
178	horizontal pleiotropy and evaluated the change in the effect estimate after excluding one variant
179	at a time from the calculation (i.e., leave-one-out analysis).
180	All MR analyses were conducted in R version 4.0.2 using the TwoSampleMR
181	package. <sup>24,26</sup>
182	Results
183	Participant characteristics
184	Baseline characteristics of participants in the FHS Offspring and Third Generation cross-
185	sectional cohorts are presented in Table 1. The mean age of participants in the Offspring cohort
186	was $60 \pm 9$ years and mean eGFR was $84 \pm 16$ mL/min/1.73m <sup>2</sup> . Seven percent of the Offspring

187	cohort had CKD at baseline, while the prevalence of DM and hypertension were 10% and 43%,
188	respectively. The mean age of participants in the Third Generation cohort was $40 \pm 9$ years and
189	mean eGFR was $102 \pm 14$ mL/min/1.73m <sup>2</sup> . Less than one percent of the Third Generation cohort
190	sample had CKD, while the prevalence of DM and hypertension were 3% and 18%, respectively.
191	Follow-up characteristics of FHS Offspring (discovery) cohort participants included in
192	longitudinal analysis of $\Delta$ eGFR, new-onset CKD, and rapid decline in eGFR are presented in
193	<b>Supplemental Table 2</b> . The mean age of Offspring cohort participants at follow-up was $66 \pm 9$
194	years and mean annual $\Delta eGFR$ between baseline and follow-up was -0.97 $\pm$ 1.73
195	mL/min/1.73m <sup>2</sup> . Among participants who did not have CKD at baseline, 3% experienced new-
196	onset CKD during follow-up while 91% maintained their eGFR at over 60 mL/min/1.73m <sup>2</sup> . The
197	remaining participants had a follow-up eGFR $< 60 \text{ mL/min}/1.73 \text{m}^2$ , but had a reduction in eGFR
198	< 30%. Eleven percent of the Offspring cohort sample included in longitudinal analysis
199	experienced rapid decline in eGFR between baseline and follow-up.
200	Discovery and validation of cross-sectional and longitudinal protein-eGFR associations
201	Cross-sectional associations of each of the 71 protein biomarkers with eGFR and the
202	incremental increase in model R <sup>2</sup> associated with each protein biomarker are presented in
203	Supplemental Table 3. Thirty-seven protein biomarkers were significantly associated with
204	eGFR (at FDR<0.05) in cross-sectional analysis, and of these, all but one (butyrylcholine
205	esterase) had an inverse association with eGFR. Six protein biomarkers were significantly
206	associated with a change in $R^2 \ge 5\%$ , including alpha-1-microglobulin (A1M), adipsin, beta-2-
207	microglobulin (B2M), cystatin C, myoglobin, and resistin. Of the 37 protein biomarkers that
208	were significantly associated with eGFR in the Offspring cohort in cross-sectional analysis, 20

#### CVD biomarkers and kidney function

209 were also significantly associated with eGFR in the Third Generation cohort at

# 210 p=0.05/37=0.00135 (Supplemental Table 4).

- 211 Longitudinal associations of each of the 71 protein biomarkers with  $\triangle$ eGFR and the incremental increase in model  $R^2$  associated with each protein biomarker are presented in 212 213 **Supplemental Table 5**. Twenty-seven protein biomarkers were significantly associated with 214  $\Delta$ eGFR at FDR<0.05. All significant protein biomarkers except two (plasminogen activator 215 inhibitor 1 [PAI1] and dipeptidyl dipeptidase [DPP4]) were inversely associated with  $\Delta eGFR$ . B2M and cystatin C were associated with the largest increases in  $R^2$  ( $\Delta R^2 = 3.3\%$  and 2.5\%. 216 217 respectively). Of the 27 proteins that were significantly associated with  $\Delta eGFR$  in the Offspring 218 cohort in longitudinal analysis, 12 were also significantly associated with  $\triangle eGFR$  in the Third 219 Generation cohort at p=0.05/27=0.00185 (Supplemental Table 6). 220 Discovery protein-trait associations: Cross-sectional associations with secondary outcomes in the 221 Offspring cohort 222 Cross-sectional associations of each of the 71 protein biomarkers with prevalent CKD 223 and the associated change in the C-statistic are presented in Supplemental Table 7. Thirty-five 224 protein biomarkers were significantly associated with prevalent CKD at FDR<0.05, and of these, 225 all but one (angiopoietin-like 3) were associated with greater log-odds of CKD. Ten protein 226 biomarkers were associated with a statistically significant change in the C-statistic. 227 Discovery protein-trait associations: Longitudinal associations with secondary outcomes in the 228 Offspring cohort 229 Five protein biomarkers were significantly associated with higher log-odds of new-onset 230 CKD at FDR<0.05 (Supplemental Table 8), while 17 protein biomarkers were significantly 231 associated with higher log-odds of rapid decline in eGFR (Supplemental Table 9). No
  - 13

CVD biomarkers and kidney function

biomarkers were associated with a significant increase in the model C-statistic for either rapiddecline in eGFR or new-onset CKD.

234 Causal inference

235 Twenty-four unique proteins were significantly associated with eGFR in both the 236 Offspring and Third Generation in cross-sectional and/or longitudinal analyses; therefore, statistical significance for all MR analyses was set at a Bonferroni-corrected p-value of 0.05/24 =237 238 0.00208. The 24 protein biomarkers associated with eGFR had a total of 25 cis-pQTL variants that overlapped with SNPs in the eGFR GWAS<sup>17</sup> and were included in MR analyses. Significant 239 240 results of MR analysis (protein  $\rightarrow$  kidney trait) for proteins that were significantly associated 241 with eGFR or with  $\triangle$ eGFR are presented in **Table 3**; full MR results for all protein biomarkers 242 with *cis*-pQTL variants are presented in **Supplemental Table 10.** Higher concentrations of 243 epidermal growth factor-containing fibulin-like extracellular matrix protein 1 (EFEMP1) and 244 melanoma cell adhesion molecule (MCAM) were significantly associated with lower eGFR ( $\beta \pm$ 245 SE -0.0064  $\pm$  0.0016 and -0.0111  $\pm$  0.0027, respectively), consistent with a potentially causal 246 relationship. Sensitivity analysis of the two EFEMP1 pQTL variants indicated no heterogeneity 247 (p=0.69, Supplemental Table 9).

248 Discussion/Conclusion

We identified a total of 43 CVD-related protein biomarkers associated with eGFR, a
continuous measure of kidney function, in cross-sectional and/or longitudinal discovery analysis.
Among these, eight proteins were significantly associated with both eGFR and ΔeGFR in the
FHS Offspring discovery sample and the FHS Third Generation validation sample. Of the 37
proteins associated with eGFR and 27 proteins associated with ΔeGFR in the FHS Offspring
cohort (i.e. discovery), 20 and 12 were associated with the corresponding trait in the FHS Third

CVD biomarkers and kidney function

Generation cohort (i.e. validation). This group of protein biomarkers included EFEMP1 and
MCAM, which were putatively causally related to eGFR in MR analysis. To our knowledge,
causal relations of protein biomarkers to CKD based on an integrative genomic approach have
not been reported previously.

259 CKD and CVD share several risk factors; identifying early mechanisms linking the two 260 disease processes may provide insights into targeted interventions to prevent or delay the onset 261 of clinically overt disease. The most notable shared risk factors are DM and hypertension. DM is associated with systemic inflammation and oxidative stress,<sup>27</sup> which in turn are associated with 262 microvascular and macrovascular complications and kidney damage.<sup>28,29</sup> Hypertension results in 263 264 prolonged exposure of the heart, kidney, and vasculature to elevated hemodynamic load that can contribute to left ventricular hypertrophy, vascular stiffening, heart failure, and CKD.<sup>30</sup> Over-265 266 activation of the renin-angiotensin-aldosterone system, which increases blood pressure through multiple mechanisms, can damage glomerular cells.<sup>13</sup> Treatment of hypertension can prevent 267 CKD progression,<sup>31</sup> while conversely, kidney disease can lead to resistant hypertension.<sup>32</sup> 268 269 Furthermore, inflammation also contributes to development of both CKD and CVD. In CKD, the 270 concentration of inflammatory proteins is inversely related to eGFR, and the cytokine interleukin (IL)-6 is a reliable predictor of adverse clinical outcomes in individuals with CKD.<sup>14,33,34</sup> Chronic 271 272 inflammation also may cause oxidative stress and endothelial dysfunction, which contribute to microvascular damage, new-onset or worsening CKD, and clinical CVD.<sup>15</sup> 273

The eGFR values observed in the FHS Offspring participants included in the discovery stage of this study were mostly in the normal range and few individuals experience a rapid decline in eGFR (n=265; 11%) or progressed to new-onset CKD (n=72; 3%) during follow-up. Under normal conditions, the glomerulus is able to freely filter proteins with molecular weight

CVD biomarkers and kidney function

278	(MW) < 70 kilodaltons (kDa), and as such, many of the proteins identified in the cross-sectional
279	and longitudinal protein-trait analyses may reflect early impaired kidney clearance of proteins
280	with low molecular weights with a resultant increase in concentrations of circulating proteins. <sup>35</sup>
281	Indeed, the vast majority of protein biomarkers showed negative associations with eGFR (i.e.,
282	lower eGFR was associated with higher protein levels), thus many of the protein biomarkers
283	identified in this study are likely downstream biomarkers of reduced kidney function.
284	Accordingly, the protein biomarkers with consistent and highly significant associations are well-
285	established markers of kidney function, and our validation in the Third Generation cohort of
286	many of the discovery associations observed in the Offspring cohort emphasize associations of
287	these proteins with kidney function in a younger, healthier population with little prevalent CKD.
288	Eight protein biomarkers were associated with both eGFR and $\Delta$ eGFR in both the Offspring and
289	Third Generation cohorts, including adipsin, adrenomedullin (ADM), A1M, B2M, collagen type
290	XVIII alpha 1 (COL18A1), cystatin C, EFEMP1, and fibroblast growth factor 23 (FGF23). Of
291	these, cystatin C (MW 15.8 kDa) and B2M (MW 13.7 kDa) were associated with all kidney traits
292	and are used in alternative eGFR calculations due to their low MW and their role as early
293	indicators of kidney impairment, and they are additionally associated with CVD outcomes. <sup>16,36–39</sup>
294	Other protein biomarkers significantly associated with eGFR and $\Delta$ eGFR are also associated
295	with inflammation and kidney disease and may represent non-traditional markers of kidney
296	function due to parallel mechanisms relevant also to CVD. A1M (MW 29.8 kDa), while having a
297	slightly higher MW than either cystatin C or B2M, has also been proposed as a biomarker of
298	kidney disease progression. <sup>40-42</sup> Similarly, adipsin (MW 27.0 kDa), ADM (MW 20.4 kDa),
299	FGF23 (MW 28.0 kDa), and endostatin, a 20 kDa fragment of the 178.2 kDa COL18A1, were all
300	reported to be elevated in the setting of kidney disease in prior studies. <sup>43–47</sup> These protein

#### CVD biomarkers and kidney function

301 biomarkers showed a robust association with kidney traits and it is possible that they reflect302 CKD risk early in the subclinical disease process.

303 We hypothesized *a priori* that a subset of proteins associated with kidney function may 304 be causal contributors to renal impairment. A recent MR analysis suggested a putatively causal 305 role of melanoma-derived growth regulatory protein (MIA), cystatin M, and carbonic anhydrase III in kidney disease.<sup>55</sup> While these proteins were not included in our assay, our MR analysis 306 307 evaluated 24 new protein biomarkers and revealed putatively causal inverse relations of 308 EFEMP1 and MCAM with eGFR. EFEMP1 is an extracellular matrix protein involved in both 309 cellular structure and signaling, and it was associated with worse eGFR cross-sectionally and 310 with  $\Delta eGFR$  longitudinally, with prevalent CKD, and with rapid decline in eGFR. A prior study 311 reported elevated EFEMP1 concentration in human kidney tissue with immunoglobulin A (IgA) nephropathy.<sup>56</sup> The causal mechanism is still unclear, but animal models suggest that EFEMP1 312 may be associated with vascular remodeling in hypertension.<sup>57</sup> MCAM, also known as MUC18 313 314 or CD146, is expressed in endothelial cells and is significantly elevated in individuals with diabetic nephropathy<sup>58,59</sup> and CKD.<sup>60,61</sup> Results of our protein-trait analysis similarly showed an 315 316 association between MCAM with both eGFR and CKD in cross-sectional analyses. 317 This study has several limitations that must be noted. The primary limitation is that a 318 custom assay used to measure the protein biomarkers in this study, which limited external 319 replication of our results. To address this limitation, we performed validation of the discovery 320 results from the FHS Offspring cohort in participants from the younger and healthier Third 321 Generation cohort in whom CKD was rare (0.3% prevalent CKD at baseline). Independent

322 external replication of the protein biomarkers identified in this study is needed.

#### CVD biomarkers and kidney function

323	In addition, we estimated kidney function based on a single creatinine measurement at
324	both baseline and follow-up, rather than using multiple eGFR values at each time point. As such,
325	our definition of CKD stage $\geq$ 3 does not mirror the recommended clinical diagnosis of CKD,
326	which requires the presence of kidney structural or functional abnormalities for at least three
327	months. <sup>62</sup> Furthermore, the younger and healthier cohort used for validation analyses limited our
328	ability to identify protein biomarkers of changing kidney function and CKD in longitudinal
329	analysis. Albuminuria and blood urea nitrogen may be clinically useful in the evaluation of
330	patients with impaired kidney function, but these data were not available for analysis in this
331	study. Our study population was limited to adults of European ancestry, which may limit
332	generalizability to other ancestry groups. Functional studies of the proteins reported to have
333	putatively causal relations to kidney function in this investigation may be warranted.

The primary strengths of this study are the large sample size and the integrative genomic approach we employed. We reported cross-sectional and longitudinal protein-trait association results to identify numerous proteins associated with kidney function and its change over time. By integrating pQTL data for the proteins we measured with genetic variants from large GWAS of kidney disease traits we identified putatively causal proteins for kidney function that represent promising candidates for further studies with the ultimate goal to better treat or prevent CKD.

The results of the comprehensive cross-sectional and longitudinal analyses in this study validate proteins that may detect of impaired kidney function early in the disease process when treatment is most likely to be beneficial. We identified robust, significant associations between 20 protein biomarkers with eGFR in cross-sectional discovery and validation analyses and 12 proteins with  $\Delta$ eGFR in longitudinal analyses both in discovery and validation. Additionally, two proteins were found to be putatively causal for reduced kidney function in causal inference

CVD biomarkers and kidney function

- testing. Further studies are necessary to determine if any of the proteins identified by MR can
- 347 serve as useful biomarkers for CKD either individually or in combination with known and
- 348 validated biomarkers.

CVD biomarkers and kidney function

## 350 References

- 351 1. Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2017 Annual Data Report:
- 352 Epidemiology of Kidney Disease in the United States. *Am J kidney Dis Off J Natl Kidney*
- 353 *Found*. 2018;71(3 Suppl 1):A7. doi:10.1053/j.ajkd.2018.01.002
- 2. Joubert BR, Felix JF, Yousefi P, et al. DNA Methylation in Newborns and Maternal
- 355 Smoking in Pregnancy: Genome-wide Consortium Meta-analysis. *Am J Hum Genet*.
- 356 2016;98(4):680-696. doi:https://doi.org/10.1016/j.ajhg.2016.02.019
- 357 3. Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic
- kidney disease, 1990–2017: a systematic analysis for the Global Burden of
- 359 Disease Study 2017. *Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-
- 360 6736(20)30045-3
- 361 4. Gansevoort RT, Matsushita K, van der Velde M, et al. Lower estimated GFR and higher
- 362 albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis
- 363 of general and high-risk population cohorts. *Kidney Int.* 2011;80(1):93-104.
- doi:10.1038/ki.2010.531
- 365 5. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular
- 366 filtration rate. Ann Intern Med. 2009;150(9):604-612. doi:10.7326/0003-4819-150-9-
- 367 200905050-00006
- 368 6. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PWF, Levy D. Predictors of New-
- 369 Onset Kidney Disease in a Community-Based Population. *JAMA*. 2004;291(7):844-850.
- doi:10.1001/jama.291.7.844
- Flint AC, Conell C, Ren X, et al. Effect of Systolic and Diastolic Blood Pressure on
  Cardiovascular Outcomes. *N Engl J Med.* 2019;381(3):243-251.

CVD biomarkers and kidney function

- 373 doi:10.1056/NEJMoa1803180
- 8. Dokken BB. The Pathophysiology of Cardiovascular Disease and Diabetes: Beyond Blood
- 375 Pressure and Lipids. *Diabetes Spectr.* 2008;21(3):160 LP 165.
- doi:10.2337/diaspect.21.3.160
- 377 9. Zelnick LR, Weiss NS, Kestenbaum BR, et al. Diabetes and CKD in the United States
- 378 Population, 2009–2014. *Clin J Am Soc Nephrol*. 2017;12(12):1984 LP 1990.
- doi:10.2215/CJN.03700417
- 380 10. United States Renal Data System. 2020 USRDS Annual Data Report: Epidemiology of
- 381 *Kidney Disease in the United States.*; 2020.
- 382 11. Kibria GM Al, Crispen R. Prevalence and trends of chronic kidney disease and its risk
- factors among US adults: An analysis of NHANES 2003-18. *Prev Med reports*.
- 384 2020;20:101193. doi:10.1016/j.pmedr.2020.101193
- 385 12. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance

386 System—United States. Published 2020. http://www.cdc.gov/ckd

- 387 13. Gajjala PR, Sanati M, Jankowski J. Cellular and Molecular Mechanisms of Chronic
- 388 Kidney Disease with Diabetes Mellitus and Cardiovascular Diseases as Its Comorbidities.
- 389 *Front Immunol.* 2015;6:340. doi:10.3389/fimmu.2015.00340
- 390 14. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J. Oxidative
- 391 stress and inflammation, a link between chronic kidney disease and cardiovascular
- 392 disease: New strategies to prevent cardiovascular risk in chronic kidney disease. *Kidney*
- 393 Int. 2008;74:S4-S9. doi:10.1038/ki.2008.516
- 394 15. Podkowińska A, Formanowicz D. Chronic Kidney Disease as Oxidative Stress- and
- 395 Inflammatory-Mediated Cardiovascular Disease. Antioxidants (Basel, Switzerland).

- 396 2020;9(8):752. doi:10.3390/antiox9080752
- 397 16. Ho JE, Lyass A, Courchesne P, et al. Protein Biomarkers of Cardiovascular Disease and
- 398 Mortality in the Community. *J Am Heart Assoc*. 2018;7(14):e008108.
- doi:10.1161/JAHA.117.008108
- 400 17. Wuttke M, Li Y, Li M, et al. A catalog of genetic loci associated with kidney function
- 401 from analyses of a million individuals. *Nat Genet*. 2019;51(6):957-972.
- 402 doi:10.1038/s41588-019-0407-x
- 403 18. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of
- 404 coronary heart disease in families: the Framinham Offspring Study. *Am J Epidemiol*.
- 405 1979;110(3):281-290. doi:10.1093/oxfordjournals.aje.a112813
- 406 19. Tsao CW, Vasan RS. Cohort Profile: The Framingham Heart Study (FHS): overview of
- 407 milestones in cardiovascular epidemiology. *Int J Epidemiol*. 2015;44(6):1800-1813.
- 408 doi:10.1093/ije/dyv337
- 409 20. Association AD. 2. Classification and Diagnosis of Diabetes: <em&gt;Standards of
- 410 Medical Care in Diabetes—2020</em&gt; *Diabetes Care*. 2020;43(Supplement 1):S14
- 411 LP-S31. doi:10.2337/dc20-S002
- 412 21. Chobanian A V, Bakris GL, Black HR, et al. Seventh Report of the Joint National
- 413 Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.
- 414 *Hypertension*. 2003;42(6):1206-1252. doi:10.1161/01.HYP.0000107251.49515.c2
- 415 22. Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical trials in
- 416 CKD: a scientific workshop sponsored by the National Kidney Foundation and the US
- 417 Food and Drug Administration. *Am J kidney Dis Off J Natl Kidney Found*.
- 418 2014;64(6):821-835. doi:10.1053/j.ajkd.2014.07.030

CVD biomarkers and kidney function

419	23.	Splansky GL,	Corey D.	, Yang Q,	, et al. T	he Third	Generation	Cohort of the	National Heart,
			2 .						,

- 420 Lung, and Blood Institute's Framingham Heart Study: Design, Recruitment, and Initial
- 421 Examination. *Am J Epidemiol*. 2007;165(11):1328-1335. doi:10.1093/aje/kwm021
- 422 24. Hemani G, Zheng J, Elsworth B, et al. The MR-Base platform supports systematic causal
- 423 inference across the human phenome. *Elife*. 2018;7. doi:10.7554/eLife.34408
- 424 25. Yao C, Chen G, Song C, et al. Genome wide mapping of plasma protein QTLs identifies
- 425 putatively causal genes and pathways for cardiovascular disease. *Nat Commun.*
- 426 2018;9(1):3268. doi:10.1038/s41467-018-05512-x
- 427 26. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
- 428 imprecisely measured traits using GWAS summary data. *PLoS Genet*.
- 429 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 430 27. Odegaard AO, Jacobs DRJ, Sanchez OA, Goff DCJ, Reiner AP, Gross MD. Oxidative
- 431 stress, inflammation, endothelial dysfunction and incidence of type 2 diabetes.

432 *Cardiovasc Diabetol.* 2016;15:51. doi:10.1186/s12933-016-0369-6

- 433 28. Lv W, Booz GW, Wang Y, Fan F, Roman RJ. Inflammation and renal fibrosis: Recent
- 434 developments on key signaling molecules as potential therapeutic targets. *Eur J*
- 435 *Pharmacol.* 2018;820:65-76. doi:10.1016/j.ejphar.2017.12.016
- 436 29. Jha JC, Ho F, Dan C, Jandeleit-Dahm K. A causal link between oxidative stress and
- 437 inflammation in cardiovascular and renal complications of diabetes. *Clin Sci (Lond)*.
- 438 2018;132(16):1811-1836. doi:10.1042/CS20171459
- 439 30. Nwabuo CC, Appiah D, Moreira HT, et al. Long-term cumulative blood pressure in young
- 440 adults and incident heart failure, coronary heart disease, stroke, and cardiovascular
- 441 disease: The CARDIA study. *Eur J Prev Cardiol*. Published online April

- 442 2020:2047487320915342. doi:10.1177/2047487320915342
- 443 31. Ptinopoulou AG, Pikilidou MI, Lasaridis AN. The effect of antihypertensive drugs on
- 444 chronic kidney disease: a comprehensive review. *Hypertens Res.* 2013;36(2):91-101.
- 445 doi:10.1038/hr.2012.157
- 446 32. Carey RM, Calhoun DA, Bakris GL, et al. Resistant Hypertension: Detection, Evaluation,
- 447 and Management: A Scientific Statement From the American Heart Association.
- 448 *Hypertens (Dallas, Tex 1979).* 2018;72(5):e53-e90.
- 449 doi:10.1161/HYP.000000000000084
- 450 33. Sun J, Axelsson J, Machowska A, et al. Biomarkers of Cardiovascular Disease and
- 451 Mortality Risk in Patients with Advanced CKD. *Clin J Am Soc Nephrol*. 2016;11(7):1163-
- 452 1172. doi:10.2215/CJN.10441015
- 453 34. Gupta J, Mitra N, Kanetsky PA, et al. Association between albuminuria, kidney function,
- 454 and inflammatory biomarker profile in CKD in CRIC. *Clin J Am Soc Nephrol*.
- 455 2012;7(12):1938-1946. doi:10.2215/CJN.03500412
- 456 35. Strober W, Waldmann TA. The role of the kidney in the metabolism of plasma proteins.
- 457 Nephron. 1974;13(1):35-66. doi:10.1159/000180368
- 458 36. Argyropoulos CP, Chen SS, Ng Y-H, et al. Rediscovering Beta-2 Microglobulin As a
- 459 Biomarker across the Spectrum of Kidney Diseases. *Front Med.* 2017;4:73.
- 460 doi:10.3389/fmed.2017.00073
- 461 37. Joseph Y, N. BE, C. MA, et al. Impact of Kidney Function on the Blood Proteome and on
- 462 Protein Cardiovascular Risk Biomarkers in Patients With Stable Coronary Heart Disease.
- 463 *J Am Heart Assoc*. 2020;9(15):e016463. doi:10.1161/JAHA.120.016463
- 464 38. Liu X, Foster MC, Tighiouart H, et al. Non-GFR Determinants of Low-Molecular-Weight

CVD biomarkers and kidney function

- 465 Serum Protein Filtration Markers in CKD. *Am J kidney Dis Off J Natl Kidney Found*.
- 466 2016;68(6):892-900. doi:10.1053/j.ajkd.2016.07.021
- 467 39. Christensson A, Ash JA, DeLisle RK, et al. The Impact of the Glomerular Filtration Rate
- 468 on the Human Plasma Proteome. *PROTEOMICS Clin Appl.* 2018;12(3):1700067.
- 469 doi:https://doi.org/10.1002/prca.201700067
- 470 40. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A,
- 471 Figlerowicz M. Chronic kidney disease-related atherosclerosis proteomic studies of
- 472 blood plasma. *Proteome Sci.* 2011;9:25. doi:10.1186/1477-5956-9-25
- 473 41. Jotwani V, Katz R, Ix JH, et al. Urinary Biomarkers of Kidney Tubular Damage and Risk
- 474 of Cardiovascular Disease and Mortality in Elders. *Am J Kidney Dis*. 2018;72(2):205-213.
  475 doi:10.1053/j.ajkd.2017.12.013
- 476 42. Vyssoulis GP, Tousoulis D, Antoniades C, Dimitrakopoulos S, Zervoudaki A, Stefanadis
- 477 C. α-1 Microglobulin as a New Inflammatory Marker in Newly Diagnosed Hypertensive
- 478 Patients: . *Am J Hypertens*. 2007;20(9):1016-1021. doi:10.1016/j.amjhyper.2007.01.010
- 479 43. Volanakis JE, Barnum SR, Giddens M, Galla JH. Renal Filtration and Catabolism of

480 Complement Protein D. *N Engl J Med.* 1985;312(7):395-399.

- 481 doi:10.1056/NEJM198502143120702
- 482 44. Velho G, Ragot S, Mohammedi K, et al. Plasma Adrenomedullin and Allelic Variation in
- 483 the ADM Gene and Kidney Disease in People With Type 2 Diabetes. *Diabetes*.
- 484 2015;64(9):3262-3272. doi:10.2337/db14-1852
- 485 45. Fliser D, Kollerits B, Neyer U, et al. Fibroblast Growth Factor 23 (FGF23) Predicts
- 486 Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD)
- 487 Study. J Am Soc Nephrol. 2007;18(9):2600 LP 2608. doi:10.1681/ASN.2006080936

- 488 46. Dieplinger B, Mueller T, Kollerits B, et al. Pro-A-type natriuretic peptide and pro-
- 489 adrenomedullin predict progression of chronic kidney disease: the MMKD Study. *Kidney*
- 490 Int. 2009;75(4):408-414. doi:10.1038/ki.2008.560
- 491 47. Pena MJ, Heinzel A, Heinze G, et al. A panel of novel biomarkers representing different
- 492 disease pathways improves prediction of renal function decline in type 2 diabetes. *PLoS*
- 493 *One*. 2015;10(5):e0120995-e0120995. doi:10.1371/journal.pone.0120995
- 494 48. Lau ES, Paniagua SM, Zarbafian S, et al. Cardiovascular Biomarkers of Obesity and
- 495 Overlap With Cardiometabolic Dysfunction. J Am Heart Assoc. 2021;10(14):e020215-
- 496 e020215. doi:10.1161/JAHA.120.020215
- 497 49. Lampón N, Hermida-Cadahia EF, Riveiro A, Tutor JC. Association between
- 498 butyrylcholinesterase activity and low-grade systemic inflammation. *Ann Hepatol.*
- 499 2012;11(3):356-363.
- 500 50. Małgorzewicz S, Skrzypczak-Jankun E, Jankun J. Plasminogen activator inhibitor-1 in
- 501 kidney pathology (Review). *Int J Mol Med.* 2013;31(3):503-510.
- 502 doi:10.3892/ijmm.2013.1234
- 503 51. Eddy AA, Fogo AB. Plasminogen Activator Inhibitor-1 in Chronic Kidney Disease:
- 504 Evidence and Mechanisms of Action. *J Am Soc Nephrol*. 2006;17(11):2999 LP 3012.
- 505 doi:10.1681/ASN.2006050503
- 506 52. Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of
- 507 dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. *Clin Sci (Lond)*.
- 508 2018;132(4):489-507. doi:10.1042/CS20180031
- 509 53. Ma L-J, Fogo AB. PAI-1 and kidney fibrosis. Front Biosci (Landmark Ed. 2009;14:2028-
- 510 2041. doi:10.2741/3361

CVD biomarkers and kidney function

	511	54.	Shi S, Koya D, Kana	saki K. Dipeptidy	l peptidase-4 and kidne	ey fibrosis in diabetes.
--	-----	-----	---------------------	-------------------	-------------------------	--------------------------

512 *Fibrogenesis Tissue Repair*. 2016;9(1):1. doi:10.1186/s13069-016-0038-0

- 513 55. Matías-García PR, Wilson R, Guo Q, et al. Plasma Proteomics of Renal Function: A
- 514 Transethnic Meta-Analysis and Mendelian Randomization Study. *J Am Soc Nephrol*.
- 515 2021;32(7):1747 LP 1763. doi:10.1681/ASN.2020071070
- 516 56. Paunas FTI, Finne K, Leh S, et al. Characterization of glomerular extracellular matrix in
- 517 IgA nephropathy by proteomic analysis of laser-captured microdissected glomeruli. *BMC*
- 518 Nephrol. 2019;20(1):410. doi:10.1186/s12882-019-1598-1
- 519 57. Lin Z, Wang Z, Li G, Li B, Xie W, Xiang D. Fibulin-3 may improve vascular health
- 520 through inhibition of MMP-2/9 and oxidative stress in spontaneously hypertensive rats.

521 *Mol Med Rep.* 2016;13(5):3805-3812. doi:10.3892/mmr.2016.5036

- 522 58. Fan Y, Fei Y, Zheng L, et al. Expression of Endothelial Cell Injury Marker Cd146
- 523 Correlates with Disease Severity and Predicts the Renal Outcomes in Patients with
- 524 Diabetic Nephropathy. *Cell Physiol Biochem*. 2018;48(1):63-74. doi:10.1159/000491663
- 525 59. Saito T, Saito O, Kawano T, et al. Elevation of serum adiponectin and CD146 levels in

526 diabetic nephropathy. *Diabetes Res Clin Pract*. 2007;78(1):85-92.

- 527 doi:10.1016/j.diabres.2007.02.014
- 528 60. Bardin N, Moal V, Anfosso F, et al. Soluble CD146, a novel endothelial marker, is
- 529 increased in physiopathological settings linked to endothelial junctional alteration.

530 *Thromb Haemost.* 2003;90(5):915-920. doi:10.1160/TH02-11-0285

- 531 61. Wang N, Fan Y, Ni P, et al. High glucose effect on the role of CD146 in human proximal
  532 tubular epithelial cells in vitro. *J Nephrol.* 2008;21(6):931-940.
- 533 62. Levin A, Stevens P, Bilous RW, et al. Kidney disease: Improving global outcomes

- 534 (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation
- and management of chronic kidney disease. *Kidney Int Suppl.* 2013;3:1-150.
- 536 doi:10.1038/kisup.2012.73
- 537
- 538

CVD biomarkers and kidney function

#### 539 Statements

- 540 **Statement of ethics:** The study protocol was reviewed and approved by the Boston University
- 541 Medical Center Institutional Review Board. All study participants provided their written
- 542 informed consent for their data and biological samples to be used.
- 543 **Conflict of interest statement**: The authors have no conflicts of interest to declare.
- 544 **Funding sources:** The Framingham Heart Study laboratory work for this project was funded by
- 545 National Institutes of Health contract N01-HC-25195. The analytical component of this project
- 546 was funded by the Division of Intramural Research, National Heart, Lung, and Blood Institute,
- 547 National Institutes of Health, Bethesda, MD (D. Levy, Principal Investigator). The work of A
- 548 Köttgen was funded by the Deutsche Forschungsgesellschaft (DFG, German Research
- 549 Foundation) Project-ID 431984000 SFB 1453.
- 550 **Disclaimer**: The views expressed in this manuscript are those of the authors and do not
- 551 necessarily represent the views of the National Heart, Lung, and Blood Institute; the National
- 552 Institutes of Health; or the U.S. Department of Health and Human Services.
- 553 Author contributions: A Keshawarz, GY Lee, S Hwang, Z Yu, and C Yao contributed to data
- analysis. All authors contributed to data interpretation. GY Lee, S Hwang, A Köttgen, and D
- 555 Levy conceived the research study. A Keshawarz drafted the manuscript. GY Lee, S Hwang, C
- 556 Yao, A Köttgen, and D Levy provided critical revisions. All authors gave final approval for
- 557 publication and are the guarantors of this work.
- 558 **Data availability statement**: The data presented in these analyses can be accessed through the
- 559 National Center for Biotechnology Information Database of Genotypes and Phenotypes
- 560 (accession number, phs00007.v29.p10).
- 561

CVD biomarkers and kidney function

## 562 Tables

## 563 **Table 1. Baseline demographic and clinical participant characteristics.**

Characteristic	Offspring cohort (n=2,873)	Third Generation cohort (n=3,951)
Age, years	$60 \pm 9$	$40 \pm 9$
Women, n (%)	1,573 (55%)	2,109 (53%)
eGFR, mL/min/1.73m <sup>2</sup>	$84 \pm 16$	$102 \pm 14$
CKD, n (%)	210 (7%)	10 (0.3%)
BMI, kg/m <sup>2</sup>	$27.95 \pm 5.22$	$26.87 \pm 5.55$
Fasting glucose, mg/dL	$102.99 \pm 24.59$	$95.02 \pm 17.9$
Systolic blood pressure, mmHg	$126.18\pm18.54$	$116.69 \pm 14.02$
Diastolic blood pressure, mmHg	$74.15 \pm 9.7$	$75.26 \pm 9.63$
Total cholesterol, mg/dL	$200.64 \pm 36.42$	$188.81 \pm 35.46$
HDL cholesterol, mg/dL	$54.41 \pm 17.2$	$54.41 \pm 16.16$
DM, n (%)	280 (10%)	114 (3%)
Hypertension, n (%)	1242 (43%)	726 (18%)
Current cigarette smoker, n (%)	362 (13%)	605 (15%)
Cholesterol-lowering medication use, n (%)	564 (20%)	341 (9%)
Prevalent cardiovascular disease, n (%)	308 (11%)	38 (1%)

564 Abbreviations: eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; BMI, body mass index;

565 HDL, high density lipoprotein; DM, diabetes mellitus

566 All continuous characteristics are presented as mean ± standard deviation. All categorical variables are presented as

total n (column %) in that category.

Protein biomarker	Protein biomarker	eGFR, Offspring		eGFR, Third Generation		ΔeGFR, Offspring		ΔeGFR, Third Generation	
	abbreviation	$\beta \pm SE$	FDR	$\beta \pm SE$	p-value	$\beta \pm SE$	FDR	$\beta \pm SE$	p-value
Adipsin		$-0.09 \pm 0.004$	<1E-27	$-0.04\pm0.002$	<1E-27	$-0.22\pm0.04$	7.3E-07	$\textbf{-0.16} \pm 0.03$	1.2E-06
Alpha-1-microglobulin	A1M	$-0.06 \pm 0.004$	<1E-27	$-0.02 \pm 0.002$	3.5E-12	$-0.18 \pm 0.04$	1.1E-05	$-0.17\pm0.03$	3.6E-08
Beta-2-microglobulin	B2M	$-0.10 \pm 0.004$	<1E-27	$-0.03 \pm 0.002$	<1E-27	$-0.43\pm0.04$	9.9E-21	$-0.13 \pm 0.03$	3.7E-05
Cystatin C		$-0.10 \pm 0.004$	<1E-27	$-0.04 \pm 0.003$	<1E-27	$-0.38 \pm 0.04$	6.8E-16	$-0.21 \pm 0.03$	1.8E-10
Epidermal growth factor containing fibulin-like extracellular matrix protein 1	EFEMP1	$-0.05 \pm 0.004$	1.7E-26	$-0.01 \pm 0.003$	8.7E-4	$-0.17 \pm 0.04$	2.8E-04	$-0.18\pm0.03$	1.6E-07
Myoglobin		$-0.07 \pm 0.004$	<1E-27	$-0.04 \pm 0.003$	<1E-27	$-0.20 \pm 0.04$	1.5E-05	$-0.13 \pm 0.04$	3.3E-04
Soluble receptor for advanced glycation endproducts	sRAGE	$-0.03 \pm 0.004$	3.0E-14	$-0.01 \pm 0.002$	6.4E-07	$-0.10 \pm 0.03$	0.02	-0.11 ± 0.03	9.4E-05
Tissue inhibitor of metalloproteinases 1	TIMP1	$-0.06 \pm 0.004$	<1E-27	$-0.02 \pm 0.002$	4.4E-16	$-0.21 \pm 0.04$	8.2E-06	$-0.14 \pm 0.03$	4.5E-06

# 568 **Table 2. Biomarkers associated with eGFR and ΔeGFR in the FHS Offspring and Third Generation cohorts.**

569

# 570 Table 3. Causal inference results: MR results for biomarkers significantly associated with eGFR in cross-sectional analyses.

Protein biomarker exposure	Protein biomarker abbreviation	Kidney trait outcome	n <sub>snp</sub>	$\beta \pm SE$	p-value
Melanoma cell adhesion molecule	MCAM	eGFR (continuous)	1	$-0.0111 \pm 0.0027$	5.11E-5
Epidermal growth factor containing fibulin-like extracellular matrix protein 1	EFEMP1	eGFR (continuous)	2	$-0.0064 \pm 0.0016$	1.04E-4

CVD biomarkers and kidney function

# 572 Figure legends

573 **Figure 1.** Overview of the study design.

